All Episodes

July 5, 2025 6 mins
# Navigating Ozempic: July 2025 Updates on Semaglutide's Impact on Health and Medicine

Discover the latest developments in Ozempic and semaglutide medications in this comprehensive podcast episode. Learn how these groundbreaking treatments are transforming approaches to diabetes and obesity management in 2025, with over three million NHS prescriptions annually. Explore clinical evidence showing 15% average weight loss, expanding applications for Type 1 diabetes, and comparison with competitor Mounjaro. The episode covers recent legal developments, supply updates, and potential future applications beyond weight management. Perfect for healthcare professionals, patients, and anyone interested in the evolving landscape of GLP-1 medications and their impact on chronic disease treatment. Subscribe for weekly insights on how these medications continue to reshape medical approaches to obesity and diabetes while balancing effectiveness with responsible use.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai
Mark as Played

Advertise With Us

Popular Podcasts

Stuff You Should Know
Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

Las Culturistas with Matt Rogers and Bowen Yang

Las Culturistas with Matt Rogers and Bowen Yang

Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.